The objective of this project is to determine the role of ?-3 derived epoxy fatty acid (?-3 epoxides) and soluble epoxide hydrolase (sEH) in mutant Kras/pancreatitis-induced carcinogenesis and to establish an efficient strategy for the prevention of pancreatic cancer using ?-3 polyunsaturated fatty acids (PUFAs) and small molecular sEH inhibitors. Anti-inflammatory/carcinogenic effects of ?-3 PUFAs are well known; but the mechanism/s remains unclear. Of the three main metabolic pathways (COX, LOX, and CYP), ?-3 PUFAs are predominantly metabolized by CYP epoxygenase/s, leading to an accumulation of ?-3 epoxy fatty acid (?-3 epoxides); and ?-3 PUFAs are poor substrates of COX and LOX. Fat1 transgenic mouse constitutively converts ?-6 to ?-3 PUFAs in all organs. Lipid metabolomics profiling in humans with ?-3 PUFAs supplementation and in Fat1 mice further demonstrate that ?-3 epoxides are major metabolites. Functional studies indicate that ?-3 epoxides are highly potent metabolites responsible for anti-inflammatory/carcinogenic actions, possibly via targeting inflammatory signals and MAP kinase. However, under physiologic conditions, these ?-3 epoxides are quickly inactivated by sEH to the diol products, and a sEH inhibitor appears crucial to stabilizing/enhancing these ?-3 epoxides actions. Thus, we hypothesize that ?-3 epoxides are the key metabolites of ?-3 PUFAs for inhibiting inflammation and carcinogenesis via targeting Kras-activated MAP kinases and inflammation signals (NF- kB and PPAR?), and that sEH inhibition is an efficient approach to enhance these ?-3 epoxides actions against pancreatitis-induced carcinogenesis. There are three specific Aims to test our hypothesis: 1) to determine a role of Fat1 transgene, sEH gene deficiency or their combination in stabilizing and enhancing ?-3 epoxides actions against mutant Kras/pancreatitis-induced carcinogenesis in PanKras mice, 2) to determine the effectiveness of the ?-3 PUFAs combined with a highly potent sEH inhibitor as an efficient chemopreventive approach against pancreatitis-induced carcinogenesis in PanKras mice, and 3) to test our hypothesis that ?-3 epoxides are the key metabolites of ?-3 PUFAs for inhibiting pancreatic cancer via targeting mutant Kras-activated signals, inflammation signals (NF-kB and PPAR?) and angiogenesis using our unique cell models and molecular biology approaches.

Public Health Relevance

Chronic pancreatitis is a well-recognized risk factor for pancreatic cancer, in which, aberrant polyunsaturated fatty acids (PUFAs) metabolism and pro-inflammatory enzyme soluble epoxide hydrolase (sEH) overexpression are believed to be the key mediators contributing to carcinogenesis. Therefore, targeting PUFAs (?-3/6) metabolism and sEH would constitute a highly significant strategy for the prevention of pancreatic cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK107767-04
Application #
9656988
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Serrano, Jose
Project Start
2016-04-05
Project End
2021-03-31
Budget Start
2019-04-01
Budget End
2021-03-31
Support Year
4
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Pathology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611